CRL-2639 Search Results


ct26 colon carcinoma cells  (ATCC)
95
ATCC ct26 colon carcinoma cells
Data reflect two weeks of CY treatment, twice weekly (i.p.) or 5 doses weekly (p.o.) dosing in the syngeneic <t>CT26</t> tumor model. (A) Frequency of Tregs in response to increasing doses of CY (i.p.). (B) Frequency of intratumoral Tregs following either p.o. or i.p. CY dosing. (C) Frequency of CD8+ T cells in response to increasing doses of CY (i.p.). (D) NK cell activity in response to increasing doses of CY (i.p.). (E) Frequency of intratumoral PMN following 40 mg/kg CY (i.p.) treatment. (F) Gating scheme for Ly6C+ CD11b+ myeloid cells and TAMs. (G) Frequency and MHCII expression of Ly6C+ CD11b+ myeloid cells in the tumor in response to 40 mg/kg CY. (H) Frequency of intratumoral MHCII lo-hi Ly6C- CD11b+ TAMs in response to 40 mg/kg CY. (I) Frequency of eosinophils following 40 mg/kg CY (i.p.) treatment. Data show the mean ± SEM. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001. Representative graphs shown of one (A–D, I), or at least two (E–H) independent experiments.
Ct26 Colon Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ct26 colon carcinoma cells/product/ATCC
Average 95 stars, based on 1 article reviews
Price from $9.99 to $1999.99
ct26 colon carcinoma cells - by Bioz Stars, 2024-10
95/100 stars
  Buy from Supplier
h508  (ATCC)
94
ATCC h508
Data reflect two weeks of CY treatment, twice weekly (i.p.) or 5 doses weekly (p.o.) dosing in the syngeneic <t>CT26</t> tumor model. (A) Frequency of Tregs in response to increasing doses of CY (i.p.). (B) Frequency of intratumoral Tregs following either p.o. or i.p. CY dosing. (C) Frequency of CD8+ T cells in response to increasing doses of CY (i.p.). (D) NK cell activity in response to increasing doses of CY (i.p.). (E) Frequency of intratumoral PMN following 40 mg/kg CY (i.p.) treatment. (F) Gating scheme for Ly6C+ CD11b+ myeloid cells and TAMs. (G) Frequency and MHCII expression of Ly6C+ CD11b+ myeloid cells in the tumor in response to 40 mg/kg CY. (H) Frequency of intratumoral MHCII lo-hi Ly6C- CD11b+ TAMs in response to 40 mg/kg CY. (I) Frequency of eosinophils following 40 mg/kg CY (i.p.) treatment. Data show the mean ± SEM. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001. Representative graphs shown of one (A–D, I), or at least two (E–H) independent experiments.
H508, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/h508/product/ATCC
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
h508 - by Bioz Stars, 2024-10
94/100 stars
  Buy from Supplier

Image Search Results


Data reflect two weeks of CY treatment, twice weekly (i.p.) or 5 doses weekly (p.o.) dosing in the syngeneic CT26 tumor model. (A) Frequency of Tregs in response to increasing doses of CY (i.p.). (B) Frequency of intratumoral Tregs following either p.o. or i.p. CY dosing. (C) Frequency of CD8+ T cells in response to increasing doses of CY (i.p.). (D) NK cell activity in response to increasing doses of CY (i.p.). (E) Frequency of intratumoral PMN following 40 mg/kg CY (i.p.) treatment. (F) Gating scheme for Ly6C+ CD11b+ myeloid cells and TAMs. (G) Frequency and MHCII expression of Ly6C+ CD11b+ myeloid cells in the tumor in response to 40 mg/kg CY. (H) Frequency of intratumoral MHCII lo-hi Ly6C- CD11b+ TAMs in response to 40 mg/kg CY. (I) Frequency of eosinophils following 40 mg/kg CY (i.p.) treatment. Data show the mean ± SEM. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001. Representative graphs shown of one (A–D, I), or at least two (E–H) independent experiments.

Journal: Oncotarget

Article Title: Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses

doi: 10.18632/oncotarget.27322

Figure Lengend Snippet: Data reflect two weeks of CY treatment, twice weekly (i.p.) or 5 doses weekly (p.o.) dosing in the syngeneic CT26 tumor model. (A) Frequency of Tregs in response to increasing doses of CY (i.p.). (B) Frequency of intratumoral Tregs following either p.o. or i.p. CY dosing. (C) Frequency of CD8+ T cells in response to increasing doses of CY (i.p.). (D) NK cell activity in response to increasing doses of CY (i.p.). (E) Frequency of intratumoral PMN following 40 mg/kg CY (i.p.) treatment. (F) Gating scheme for Ly6C+ CD11b+ myeloid cells and TAMs. (G) Frequency and MHCII expression of Ly6C+ CD11b+ myeloid cells in the tumor in response to 40 mg/kg CY. (H) Frequency of intratumoral MHCII lo-hi Ly6C- CD11b+ TAMs in response to 40 mg/kg CY. (I) Frequency of eosinophils following 40 mg/kg CY (i.p.) treatment. Data show the mean ± SEM. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001. Representative graphs shown of one (A–D, I), or at least two (E–H) independent experiments.

Article Snippet: CT26 colon carcinoma cells (CRL-2639) and 4T1 mammary carcinoma cells (CRL-2539) were purchased from ATCC and authenticated by ATCC using COI analysis.

Techniques: Activity Assay, Expressing

(A) Illustration of the syngeneic mouse tumor models. Briefly, CY (40 mg/kg) was given i.p. and SD-101 (50 μg/injection) was given i.t., twice weekly. (B) Tumor growth at the injected and non-injected sites was monitored (n= 24/group at d12 and d15, n=18/group at d19, n=12/group at d22 and n=6/group at d25 and d28; mice were removed for mechanistic evaluation during the course of the study). (C) Cumulative data of the fold increase in non-injected tumor volume following 4 doses of CY and 3 doses of SD-101 from 7 experiments, n=45-57/group. (D) Long-term survival of mice bearing CT26 s.c. tumor on both flanks, receiving saline, monotherapy (CY i.p. or SD-101 i.t.) or combination therapy as illustrated in (A). Experiment schedule was similar as in (B) but with longer treatment times, as indicated on the survival curve (D), n=10/group. (E) Data from (C) was divided according to the tumor size at the start of CY treatment (<100 mm 3 , 100-200 mm 3 and > 250 mm 3 ). Resulting groups ranged from 9 to 27 mice, with an average of 18 mice per group. Data show the mean ± SEM, * compared with control, * compared with SD-101, * compared with CY. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001.

Journal: Oncotarget

Article Title: Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses

doi: 10.18632/oncotarget.27322

Figure Lengend Snippet: (A) Illustration of the syngeneic mouse tumor models. Briefly, CY (40 mg/kg) was given i.p. and SD-101 (50 μg/injection) was given i.t., twice weekly. (B) Tumor growth at the injected and non-injected sites was monitored (n= 24/group at d12 and d15, n=18/group at d19, n=12/group at d22 and n=6/group at d25 and d28; mice were removed for mechanistic evaluation during the course of the study). (C) Cumulative data of the fold increase in non-injected tumor volume following 4 doses of CY and 3 doses of SD-101 from 7 experiments, n=45-57/group. (D) Long-term survival of mice bearing CT26 s.c. tumor on both flanks, receiving saline, monotherapy (CY i.p. or SD-101 i.t.) or combination therapy as illustrated in (A). Experiment schedule was similar as in (B) but with longer treatment times, as indicated on the survival curve (D), n=10/group. (E) Data from (C) was divided according to the tumor size at the start of CY treatment (<100 mm 3 , 100-200 mm 3 and > 250 mm 3 ). Resulting groups ranged from 9 to 27 mice, with an average of 18 mice per group. Data show the mean ± SEM, * compared with control, * compared with SD-101, * compared with CY. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001.

Article Snippet: CT26 colon carcinoma cells (CRL-2639) and 4T1 mammary carcinoma cells (CRL-2539) were purchased from ATCC and authenticated by ATCC using COI analysis.

Techniques: Injection

(A) Tumor growth at the injected and non-injected flanks of 4T1 s.c. tumor-bearing mice, n=10/group. Illustration of the syngeneic mouse 4T1 tumor model is found in and treatment schedule is illustrated in (A). (B) Cumulative data of fold increase in 4T1 non-injected tumor volume following 4 doses of CY and 3 doses of SD-101 from 3 experiments, n= 27-35/group. (C) Illustration of CT26 i.v. tumor-burdened lung model. CT26 cells were injected i.v. to allow dissemination into the lungs. Mice received SD-101 i.n. (10 μg/50 μl saline) biweekly, and/or CY p.o. (16 mg/kg body weight) treatment 5 times per week. (D) Mice bearing CT26 lung tumors from (C), n=26-33/group were monitored for long-term survival. Data shown represents the combination of 3 independent experiments, n=34-36/group. Data show the mean ± SEM, * compared with control, * compared with SD-101, * compared with CY. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001.

Journal: Oncotarget

Article Title: Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses

doi: 10.18632/oncotarget.27322

Figure Lengend Snippet: (A) Tumor growth at the injected and non-injected flanks of 4T1 s.c. tumor-bearing mice, n=10/group. Illustration of the syngeneic mouse 4T1 tumor model is found in and treatment schedule is illustrated in (A). (B) Cumulative data of fold increase in 4T1 non-injected tumor volume following 4 doses of CY and 3 doses of SD-101 from 3 experiments, n= 27-35/group. (C) Illustration of CT26 i.v. tumor-burdened lung model. CT26 cells were injected i.v. to allow dissemination into the lungs. Mice received SD-101 i.n. (10 μg/50 μl saline) biweekly, and/or CY p.o. (16 mg/kg body weight) treatment 5 times per week. (D) Mice bearing CT26 lung tumors from (C), n=26-33/group were monitored for long-term survival. Data shown represents the combination of 3 independent experiments, n=34-36/group. Data show the mean ± SEM, * compared with control, * compared with SD-101, * compared with CY. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001.

Article Snippet: CT26 colon carcinoma cells (CRL-2639) and 4T1 mammary carcinoma cells (CRL-2539) were purchased from ATCC and authenticated by ATCC using COI analysis.

Techniques: Injection

(A) CT26 cells were implanted s.c. in both flanks (n=4-5/group). CY (40 mg/kg) was given i.p. and SD-101 (50 μg/injection) was injected into the right flank (injected site). RNA was extracted from tumors as indicated in the experimental schema (A). (B) Number of differentially expressed (DE) genes in the treatment groups that exhibit a log 2 fold change >0.6 (>1.5 fold change) and P<0.05 compared to control group at the indicated time points. (C) Venn diagrams of the number of overlapping DE genes of the non-injected tumors between treatment conditions. (D) Heatmap of directed global significance scores (non-injected tumor), which display the extent to which a gene sets’ genes are up or down-regulated with the treatments relative to control at that time point. (E) Pathway scores (non-injected tumor), which summarize the data from a pathway’s genes with a single score, of select functional pathways. (F) Cell type scores (non-injected tumor), which measure the intratumoral abundance of immune cells using specific gene signatures. Data are mean ± SEM, * compared with control, * compared with SD-101, * compared with CY. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001.

Journal: Oncotarget

Article Title: Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses

doi: 10.18632/oncotarget.27322

Figure Lengend Snippet: (A) CT26 cells were implanted s.c. in both flanks (n=4-5/group). CY (40 mg/kg) was given i.p. and SD-101 (50 μg/injection) was injected into the right flank (injected site). RNA was extracted from tumors as indicated in the experimental schema (A). (B) Number of differentially expressed (DE) genes in the treatment groups that exhibit a log 2 fold change >0.6 (>1.5 fold change) and P<0.05 compared to control group at the indicated time points. (C) Venn diagrams of the number of overlapping DE genes of the non-injected tumors between treatment conditions. (D) Heatmap of directed global significance scores (non-injected tumor), which display the extent to which a gene sets’ genes are up or down-regulated with the treatments relative to control at that time point. (E) Pathway scores (non-injected tumor), which summarize the data from a pathway’s genes with a single score, of select functional pathways. (F) Cell type scores (non-injected tumor), which measure the intratumoral abundance of immune cells using specific gene signatures. Data are mean ± SEM, * compared with control, * compared with SD-101, * compared with CY. * indicates P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001.

Article Snippet: CT26 colon carcinoma cells (CRL-2639) and 4T1 mammary carcinoma cells (CRL-2539) were purchased from ATCC and authenticated by ATCC using COI analysis.

Techniques: Injection, Functional Assay